"Parkinson Disease" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
Descriptor ID |
D010300
|
MeSH Number(s) |
C10.228.140.079.862.500 C10.228.662.600.400 C10.574.812
|
Concept/Terms |
Parkinson Disease- Parkinson Disease
- Idiopathic Parkinson's Disease
- Lewy Body Parkinson Disease
- Lewy Body Parkinson's Disease
- Primary Parkinsonism
- Parkinsonism, Primary
- Parkinson Disease, Idiopathic
- Parkinson's Disease
- Parkinson's Disease, Idiopathic
- Parkinson's Disease, Lewy Body
- Idiopathic Parkinson Disease
- Paralysis Agitans
|
Below are MeSH descriptors whose meaning is more general than "Parkinson Disease".
Below are MeSH descriptors whose meaning is more specific than "Parkinson Disease".
This graph shows the total number of publications written about "Parkinson Disease" by people in this website by year, and whether "Parkinson Disease" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 1 | 1 | 2 |
1995 | 3 | 1 | 4 |
1996 | 0 | 1 | 1 |
1997 | 2 | 2 | 4 |
1998 | 1 | 0 | 1 |
2001 | 1 | 1 | 2 |
2002 | 2 | 1 | 3 |
2003 | 0 | 1 | 1 |
2004 | 1 | 2 | 3 |
2005 | 5 | 3 | 8 |
2006 | 2 | 0 | 2 |
2007 | 5 | 1 | 6 |
2008 | 10 | 6 | 16 |
2009 | 13 | 0 | 13 |
2010 | 7 | 1 | 8 |
2011 | 8 | 0 | 8 |
2012 | 12 | 2 | 14 |
2013 | 7 | 0 | 7 |
2014 | 7 | 0 | 7 |
2015 | 15 | 0 | 15 |
2016 | 7 | 2 | 9 |
2017 | 10 | 1 | 11 |
2018 | 9 | 0 | 9 |
2019 | 4 | 0 | 4 |
2020 | 10 | 1 | 11 |
2021 | 11 | 0 | 11 |
2022 | 10 | 0 | 10 |
2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Parkinson Disease" by people in Profiles.
-
Are Standardized Tests Sensitive to Early Cognitive Change in Parkinson's Disease? Psychopharmacol Bull. 2023 Feb 28; 53(1):19-29.
-
PGRN deficiency exacerbates, whereas a brain penetrant PGRN derivative protects, GBA1 mutation-associated pathologies and diseases. Proc Natl Acad Sci U S A. 2023 01 03; 120(1):e2210442120.
-
Inhibition of Calpain Attenuates Degeneration of Substantia Nigra Neurons in the Rotenone Rat Model of Parkinson's Disease. Int J Mol Sci. 2022 Nov 10; 23(22).
-
Study in Parkinson's disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trial. Trials. 2022 Oct 06; 23(1):855.
-
Deep Learning for Daily Monitoring of Parkinson's Disease Outside the Clinic Using Wearable Sensors. Sensors (Basel). 2022 Sep 09; 22(18).
-
Immunoglobulin ? chain allotypes and humoral immunity to HSV1 in Parkinson's disease. J Neuroimmunol. 2022 10 15; 371:577948.
-
Inclusion of Non-English-Speaking Participants in Studies of Parkinson's Disease: A Call to Action. Mov Disord. 2022 10; 37(10):1990-1995.
-
Restricting a-synuclein transport into mitochondria by inhibition of a-synuclein-VDAC complexation as a potential therapeutic target for Parkinson's disease treatment. Cell Mol Life Sci. 2022 Jun 19; 79(7):368.
-
Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations. Transl Neurodegener. 2022 05 02; 11(1):24.
-
Calpain activation and progression of inflammatory cycles in Parkinson's disease. Front Biosci (Landmark Ed). 2022 01 13; 27(1):20.